APB-231: An Investigation Into the Short Term Effect of APOMINE in Patients with Osteoporosis or Low Bone Mass

ATGFB1-001-01: Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients with Early Stage Diffuse Systemic Sclerosis

AMD3100-2201: AMD3100 With Busulfan, Fludarabine and Thymoglobulin for Allogeneic Stem Cell Transplant for AML and MDS

AMD3100-2113: The Effect of Rituximab on Mobilization With AMD3100 Plus G-CSF in Patients With Relapsed or Refractory NHL or HD

GC1008FSGS00505: Phase I, Multicentre, Open-Label, Dose-Escalating, Study of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS

GD3-163-201: Cross-Over Study of Sevelamer Hydrochloride and Sevelamer Carbonate

AMD3100-1101: Safety, PK, and Hematological Activity Of AMD3100 In Subjects With Renal Impairment

AMD3100-2112: AMD3100 With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed HSC Collection/Attempts

DCREN-005-01: Safety/Efficacy of a Vaccine Prepared from Dendritic Cells Combined with Tumor Cells to Treat Advanced Kidney Cancer

Fabry Disease Registry

GC100800103: Study of GC1008 in Patients with Idiopathic Pulmonary Fibrosis (IPF)

GC100800305: Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma

GD3-170-301: A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea

GD3-199-301: Study to Compare Sevelamer Carbonate Powder to Sevelamer Hydrochloride Tablets in Patients With Chronic Kidney Disease on Hemodialysis

GMA16100104: Pharmacokinetics and Pharmacodynamic Study of GMA161 in Patients With Idiopathic Thrombocytopenic Purpura

GTC-134-102: Iron Balance Study of DFO and GT56-252 in Patients with Transfusional Iron Overload Secondary to Beta-Thalassemia

GTC-80-203; GT1105: A Study of GT160-246 Versus Vancomycin in Patients with Clostridium Difficile-Associated Diarrhea

HYLA-001-01: A Double-Blinded Evaluation of Safety and Efficacy of Hylaform and Hylaform Plus Compared to Zyplast

ILX651-211: Study of ILX651 in Patients with Inoperable Locally Advanced or Metastatic Melanoma

ILX651-231: Study of ILX651 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma

ILX651-241: Study of ILX651 in Patients with Hormone-Refractory Prostate Cancer Previously Treated with Docetaxel

MPS I Registry: Mucopolysaccharidosis I (MPS I) Registry

NADGL00106: A Study to Compare Subject Comfort During and After Injections With the Study Products and the Safety of the Non-FDA Approved Product for the Correction of Nasolabial Folds (NLFs)

NM-103: A Study of NM-3 Administered Orally in Patients with Advanced Solid Tumors

Pompe Disease Registry

SMC00202: Study to Examine the Safety and Effectiveness of Implanted Skeletal Muscle Cells (Cells Removed From the Thigh Muscle) Into Scarred Areas of Heart Muscle After Heart Attack

SYNV-004-02: A Study of the Safety and Efficacy of Synvisc and Depo-Medrol in Patients with Osteoarthritis of the Hip

SYNV-003-02: A Study of the Safety and Efficacy of Synvisc in Patients with Symptomatic Ankle Osteoarthritis

SYNV-002-01: A Study of the Safety and Efficacy of Synvisc in Patients with Symptomatic Shoulder Osteoarthritis

SYNV00704: A Study of the Safety and Efficacy of Synvisc in Patients with Symptomatic Osteoarthritis of the Knee

SVCARB00205: Study to Demonstrate Equivalence of Sevelamer Carbonate Powder and Sevelamer Hydrochloride Tablets in Haemodialysis Patients

SPACK00104ORP: Efficacy of Seprapack Sinus Dressing Versus No Dressing in the Prevention of Intranasal Adhesions Following Sinus Surgery

SF97-0601: Seprafilm in the Reduction of Incidence of Bowel Obstruction in General Surgery

PD96-1101: Phase 2, Double-Blind, Randomized, Controlled Multi-Center Clinical Trial of the Safety and Efficacy of Transplanted Fetal Porcine Cells in Patients with Parkinson's Disease

PADHIF00704: Safety and Efficacy Study of Ad2/Hypoxia Inducible Factor (HIF)-1α/VP16 Gene Transfer in Patients with Intermittent Claudication

TOL26700606: A Study of the Absorption of GT267-004 in Patients With Clostridium Difficile-Associated Diarrhea

AMD11070-1001: A Study of AMD11070 in HIV-Infected Patients Carrying X4-Tropic Virus

International Collaborative Gaucher Group (ICGG) Gaucher Registry

GD3170302: A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C. Difficile-Associated Diarrhea

SPHINGO00605: Safety Study of rhASM Enzyme Replacement Therapy in Adults With Acid Sphingomyelinase Deficiency (Niemann-Pick Disease)

AAVhAADC2003: A Study of AAV-hAADC-2 in Subjects With Parkinson's Disease

THYR01605: A New Study to Follow-Up Thyroid Cancer Patients Who Participated in a Previous Study. The Latter Study Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.

AGAL00599: A Study of the Safety and Efficacy of Fabrazyme in Patients with Fabry Disease

AGAL00800: A Study of the Safety and Efficacy of Fabrazyme as Compared to Placebo in Patients with Advanced Fabry Disease

AGAL01601: A Study of Fabrazyme in Pediatric Patients with Fabry Disease

AGAL01701: A Study of the Safety and Efficacy of Fabrazyme in Patients with Fabry Disease

AGAL02503: A Study of the Safety and Efficacy of Fabrazyme in Patients with Fabry Disease

AGAL03004: A Long Term Safety and Efficacy Study of Fabrazyme Replacement Therapy in Japanese Patients with Fabry Disease

AGAL03204: A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients with Cardiac Fabry Disease

AGAL03505: A Study in Patients With Fabry Disease Who Are on Chronic Hemodialysis Therapy for Treatment of End-Stage Renal Insufficiency.

AGLU02905: Screening Protocol to Evaluate Acid Alpha-Glucosidase (GAA) Activity and GAA Gene Mutations in Patients With Late Onset Pompe Disease

AGLU02804: Single-Center, Open-Label Study of Safety, Pharmacokinetics and Efficacy of rhGAA in Patients With Late-Onset Pompe Disease

AGLU02603: Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients With Late-Onset Pompe Disease

AGLU02403: Extension Study of Patients With Infantile-Onset Pompe Disease Who Were Previously Enrolled in Protocol AGLU01602

AGLU02303: A Prospective, Observational Study in Patients With Late-Onset Pompe Disease

AGLU02203: Expanded Access Use of Myozyme (Alglucosidase Alfa) in Patients with Infantile-Onset Pompe Disease

AGLU01702: rhGAA in Patients with Infantile-Onset Glycogen Storage Disease-II (Pompe Disease)

AGLU01602: A Study of the Safety and Efficacy of rhGAA in Patients With Infantile-Onset Pompe Disease

AGLU01502: A Study of the Safety and Pharmacokinetics of rhGAA in Siblings with Glycogen Storage Disease Type II

AGLU00100: Safety and Efficacy of Recombinant Human Acid Alpha-Glucosidase in the Treatment of Classical Infantile Pompe Disease

HECT00106: A Phase 4 Pharmacokinetic Study of Hectorol Injection and Zemplar Injection in CKD Subjects on Hemodialysis

HECT00306: A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection

CARTCEL01299: Study of the Treatment of Articular Repair (STAR)

RC961101: A Multicenter Study of the Efficacy of Cerezyme in Testing Skeletal Disease in Patients With Type I Gaucher Disease.

ALID00601: Phase 3 Extension Study of the Safety and Efficacy of Aldurazyme® (Laronidase) in Mucopolysaccharidosis I (MPS I) Patients

GTC68209: Study to Compare Once A Day Sevelamer Dosing With Three Times Per Day Sevelamer Dosing

REN00304: Study of Safety and Efficacy of Renagel® Compared with Calcium Acetate in Patients with Peritoneal Dialysis

GTC68401: Dialysis Clinical Outcomes Revisited (DCOR) Trial

ALID01402: A Study Evaluating the Safety and Pharmacokinetics of Aldurazyme® (Laronidase) in MPS I Patients Less Than 5 Years Old

ALID01703: A Dose-Optimization Study of Aldurazyme® (Laronidase) in Patients with Mucopolysaccharidosis I (MPS I) Disease

ALID01803: A Study of the Effect of Aldurazyme® (Laronidase) Treatment on Lactation in Female Patients With Mucopolysaccharidosis I (MPS I) and Their Breastfed Infants

ALID02003: A Study Investigating the Relationship Between the Development of Laronidase Antibody and Urinary GAG Levels in Aldurazyme® Treated Patients

ALID02205: Study of Aldurazyme® Replacement Therapy in Patients With Mucopolysaccharidosis I (MPS I)

SMC1011010: An Open-Label, Prospective, Randomized, Multi-Center, Phase II Comparative Trial of Thymoglobulin Versus Simulect for the Prevention of Delayed Graft Function and Acute Allograft Rejection in Renal Allograft Recipients

SMC1011025: A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection

SMC1011026: Thymoglobulin to Prevent Acute Graft Vs. Host Disease (GvHD) in Patients with Acute Lymphocytic Leukemia (ALL) or Acute Myelogenous Leukemia (AML) Receiving a Stem Cell Transplant

THYR00800: Comparison of the Safety and Successful Ablation of Thyroid Remnant in Post-Thyroidectomized Euthyroid Patients (i.e. Patients Administered Thyrogen) Versus Hypothyroid Patients (No Thyrogen) Following 131I Administration

THYR01205: Study Comparing Thyrogen Versus a Modified Release of Recombinant Human Thyroid Stimulating Hormone

AMD31002104: Mobilization of Stem Cells With AMD3100, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin’s Lymphoma Patients

AMD3100-2109: AMD3100 in MM or NHL Patients Predicted to be Unable to Mobilize ≧2x10e6 CD34+ Cells in 3 Apheresis Days With G-CSF

AMD31002108: Treatment With AMD3100 in MM Patients to Mobilize PBCs For Collection and for Transplantation

AMD3100-2105: Mobilization of Stem Cells With AMD3100 and G-CSF in Non-Hodgkin’s Lymphoma and Multiple Myeloma Patients

AMD3100EU21: Treatment With AMD3100 in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients

AGLU03105: A Prospective, Open-Label Study of the Effect and Safety of rhGAA in Patients With Advanced Late-Onset Pompe Disease Receiving Respiratory Support.

AGLU03206: Late-Onset Treatment Study Extension Protocol

AGAL02603: A Study of the Effects of Fabrazyme on Mother's Lactation and on the Growth, Development and Immunologic Response of Their Infants

TOL26700706: A Study to Look at the Safety, Tolerability, Effectiveness and Absorption (How the Drug is Taken up) of a Newly Developed Medication Called Exodif™ (Tolevamer Potassium Sodium) Tablets in Patients With Clostridium Difficile-Associated Diarrhea

AGLU02704: Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Efficacy and Pharmacokinetics of Myozyme in Patients With Late-Onset Pompe Disease

AMD31002106: AMD3100 Added to a Mobilizing Regimen of G-CSF to Increase the Number of PBSCs in Patients with Hodgkin’s Disease

AMD31003101: Mobilization of Stem Cells With AMD3100 in Non-Hodgkin’s Lymphoma Patients

AMD31003102: Mobilization of Stem Cells With AMD3100 in Multiple Myeloma Patients

AMD3100C201: AMD3100 Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF

AGLU03306: Dose and Dose Interval Study of Myozyme®

AGLU03907: Myozyme Temporary Access Program (MTAP)

AVS00103: Comparison of Hylastan to Methylprednisolone Acetate in Patients with Symptomatic Osteoarthritis of the Knee

BCICH151: Safety and Efficacy of Doxercalciferol in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism

Cartilage Repair Registry: The Objectives of the Cartilage Repair Registry is to Report Long Term Efficacy and Safety of Cartilage Repair Procedures in Registry Patients

CZ01101: Safety and Efficacy of Cerezyme® Infusions Every 4 Weeks Versus Every 2 Weeks in Type 1 Gaucher Disease

DGE00105: A Study to Compare the Safety and Effectiveness of a Non-FDA Approved Device (DGE) and an FDA Approved Device for the Correction of Nasolabial Folds (NLFs)

GD3165101: A Safety and Efficacy Study of DENSPM in Patients with Liver Cancer Who Are Not Eligible for Surgical Care

GZGD0030: A Study of the Efficacy and Safety of Genz-112639 in Type 1 Gaucher Patients

HECT00406: A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis

HYLA00204: A Post-Market Study to Evaluate Adverse Event Incidence Rates in Patients With Skin of Color Undergoing Correction of Nasolabial Folds With Hylaform, Hylaform Plus and Captique.

THYMO102700103: A Study to Evaluate the Effect of Thymoglobulin Induction Therapy and Reduced Doses of Calcineurin Inhibitors on the Incidence of Liver Transplant Rejection

MRTSH01505: Study to Determine the Dose, the Safety and Effectiveness of a New Drug, Modified Release rhTSH, in Patients With Multinodular Goiter

CLO151: Clofarabine in Adult Patients With Advanced Solid Tumors

CLO152: Study of Oral Clofarabine Administered Daily for 5 Days in Adult Patients With Refractory Solid Tumors

CLO221: Phase II Study of Clofarabine in Adult Patients with Refractory or Relapsed Acute Myelogenous Leukemia

CLO222: Phase II Study of Clofarabine in Pediatric Acute Myelogenous Leukemia (AML) Patients

CLO212: Phase II Study of Clofarabine in Pediatric Acute Lymphoblastic Leukemia (ALL)

CLO34100405: A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML) (CLASSIC I)

CLO24300606: A study of Clofarabine for Older Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) (CLASSIC II)

CLOMDS02507: A Dose Confirmation Study of Oral Clofarabine for Previously Treated Adult Patients With Intermediate-2 or High Risk Myelodysplastic Syndromes (MDS).

CAM111: Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies

CAM203: Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Patients With Previously Treated B-Cell Chronic Lymphocytic Leukemia

CAM307: Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) Vs Chlorambucil in Patients with Progressive B-Cell Lymphocytic Leukemia

CAM314: Fludara Plus Alemtuzumab (Campath, MabCampath) Vs Fludara Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients

CAMNHL232: Phase I/II Study of CAMPATH in Patients with Relapsing or Refractory Non-Hodgkin’s Lymphoma

CAMNHL233: Rituximab Plus CAMPATH in Patients with Relapsed/Refractory Low-Grade or Follicular, CD20-Positive, B-Cell NHL

CAMMS223: A Phase II Study Comparing Low- and High-Dose CAMPATH and High-Dose Rebif in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis

Protocol no.: Title (style = CorpTitle)

CLO21800205: A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias.

CAMMS32400507: Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis, Study Two (CARE-MS SM II)

CAMMS323: Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis, Study One (CARE-MS SM I)